Pitchbook recently reported on a EUR 3.3 million A round in the Netherlands. The venture, Synkerkine Pharma, received the funds from Thuja Capital.

The Players

Synkerkine Pharma was founded in 2018 to leverage powerful intellectual property developed by the University Medical Center Utrecht (UMCU). Synkerkine Pharma CEO Hans Preusting has accumulated considerable experience and expertise building various biotech life science ventures.  Thuja Capital Management BV, founded in 2005, is a Dutch venture capital group emphasizing health and life science investments.

The IP

UMCU runs the Niels Eijkelkamp Lab which focuses on the interaction between the nervous system and immune system and how these interactions may contribute to chronic pain.  Back in April 2018 they reported that chronic pain is difficult to treat and new approaches to resolve persistent pain are desperately needed. UMCU’s lab understood that anti-inflammatory cytokines represent promising candidates for treating debilitating pain conditions due to their capacity to regulate aberrant neuro-immune interactions.

Anti-inflammatory cytokines are promising candidates for treating debilitating pain conditions due to their capacity to regulate aberrant neuro-immune interactions. However, physiologically they work in a network of various cytokines, and therefore their therapeutic effect may not be optimal when used as stand-alone drugs. To overcome this limitation, the Niels Eijkelkamp Lab developed a fusion protein of the anti-inflammatory cytokines IL4 and IL10. In this ResearchGate link, they describe the methods for production and quality control of IL4-10 recombinant fusion protein and additionally test the effectiveness of the IL4-10 fusion protein to resolve pain in a mouse model of persistent inflammatory pain.

Source: pitchbook.com

Pin It on Pinterest